Merck Takes A New Shot At Alzheimer’s With Cerevance Deal

Pays $25m Upfront

 
• By Ayisha Sharma

The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.  

Man with Alzheimer's disease
An Estimated 6.5 Million People In The US Have Alzheimer's Disease • Source: Shutterstock

More from Deals

More from Business